Discontinuation of Disease-Modifying Therapy in Multiple Sclerosis: Should We Stay or Should We Go?

Eva M. M. Strijbis*, Anne Kerbrat, John R. Corboy

*Corresponding author for this work

Research output: Contribution to journalComment/Letter to the editorAcademic

Original languageEnglish
Pages (from-to)787-788
Number of pages2
JournalJAMA Neurology
Issue number7
Early online date2021
Publication statusPublished - Jul 2021

Cite this